八味龍鉆顆粒對(duì)佐劑性關(guān)節(jié)炎大鼠的影響

羅宇東++吳玉強(qiáng)+++龐宇舟++譚安薔+米阿娜

[摘要] 目的 研究八味龍鉆顆粒對(duì)佐劑性關(guān)節(jié)炎大鼠的影響。 方法 將60只大鼠隨機(jī)分為空白對(duì)照組、模型組、雷公藤多苷片組和八味龍鉆顆粒低、中、高劑量組，除空白對(duì)照組外，其余各組均按每只0.1 mL弗氏完全佐劑（FCA）注射于大鼠左后足跖內(nèi)。實(shí)驗(yàn)第8天開(kāi)始灌胃給藥，每日1次，給藥體積10 mL/kg，八味龍鉆顆粒劑量為5.9、11.8、23.6 g/kg，雷公藤多苷片為0.009 45 g/kg，空白對(duì)照組及模型組予等體積蒸餾水，連續(xù)灌胃給藥21 d。觀察佐劑性關(guān)節(jié)炎模型大鼠踝關(guān)節(jié)腫脹度及病理改變情況，并采用酶聯(lián)免疫吸附測(cè)定（ELISA）法檢測(cè)大鼠血清及關(guān)節(jié)組織勻漿中白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子α（TNF-α）的含量。 結(jié)果 與空白對(duì)照組比較，造模8 d起模型組及各給藥組大鼠足趾厚度顯著增加，差異有統(tǒng)計(jì)學(xué)意義（P < 0.01或P < 0.05）；與模型組比較，造模29 d八味龍鉆顆粒高劑量組足趾腫脹度明顯降低，差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；病理檢測(cè)顯示，八味龍鉆顆粒高劑量組滑膜細(xì)胞增生程度、炎癥細(xì)胞浸潤(rùn)程度均減輕；八味龍鉆顆粒各劑量組血清IL-1β、TNF-α含量與模型組比較差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）。 結(jié)論 八味龍鉆顆粒能降低佐劑性關(guān)節(jié)炎大鼠的足趾腫脹度，減輕滑膜細(xì)胞增生及炎癥細(xì)胞浸潤(rùn)，對(duì)大鼠佐劑性關(guān)節(jié)炎病理模型具有一定的改善作用。

[關(guān)鍵詞] 八味龍鉆顆粒；類(lèi)風(fēng)濕關(guān)節(jié)炎；佐劑性關(guān)節(jié)炎

[中圖分類(lèi)號(hào)] R322.72 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1673-7210（2017）11（c）-0026-05

Effects of Bawei Longzuan Granules in rats with adjuvant arthritis

LUO Yudong1，2 WU Yuqiang1 PANG Yuzhou2，3 TAN Anqiang1 MI A'na3

1.Pharmaceutical Factory， Guangxi University of Chinese Medicine， Guangxi Zhuang Autonomous Region， Nanning 530023， China； 2.Key Laboratory of Zhuang Medicine Prescriptions Basis and Application Research of Guangxi Colleges and Universities， Guangxi Zhuang Autonomous Region， Nanning 530001， China； 3.College of Zhuang Medicine， Guangxi University of Chinese Medicine， Guangxi Zhuang Autonomous Region， Nanning 530001， China

[Abstract] Objective To study the effects of Bawei Longzuan Granules in rats with adjuvant arthritis. Methods Sixty SD rats were randomly divided into blank control group， model group， Tripterygium Wilfordii Tablets group， and low， medium， high dose of Bawei Longzuan Granules group. Except for blank control group， the other groups were only given 0.1 mL of Freund complete adjuvant （FCA） injection into the left-hind feet of each rat. At the eighth day of the experiment， intragastric administration was started， once a day， the dosing volume was 10 mL/kg， the dosages of Bawei Longzuan Granules were 5.9， 11.8， 23.6 g/kg， the dosage of Tripterygium Wilfordii Tablets was 0.009 45 g/kg， blank control group and model group were given same volume of distilled water， continuous intragastric administration for 21 days. The conditions of ankle joint swelling and pathologic changes in model rats with adjuvant arthritis were observed， and enzyme-linked immunosorbent assay （ELISA） was used to detect the contents of interleukin-1β （IL-1β）， tumor necrosis factor α （TNF-α） in serum and joint tissue homogenate of rats. Results Compared with blank control group， started from the eighth day of making model， the feet thickness of model group and all medication groups was increased， the differences were statistically significant （P < 0.01 or P < 0.05）； compared with model group， the swelling degree of toes in high dose of Bawei Longzuan Granules group at the 29th day of modeling was decreased， the difference was statistically significant （P < 0.05）； the pathological examination showed that the proliferative degree of synovial cells and the invasive degree of inflammatory cells in high dose of Bawei Longzuan Granules group were all reduced； there were no statistically significant differences of the contents of serum IL-1β， TNF-α in each dose of Bawei Longzuan Granules group compared with those of model group （P > 0.05）. Conclusion Bawei Longzuan Granules can decrease the swelling degree of toes in rats with adjuvant arthritis， reduce the proliferation of synovial cells and inflammatory cell infiltration， which has certain improving effects for the pathological model of rats with adjuvant arthritis.endprint

[Key words] Bawei Longzuan Granules； Rheumatoid arthritis； Adjuvant arthritis

類(lèi)風(fēng)濕關(guān)節(jié)炎（RA）是一種常見(jiàn)慢性病及疑難疾病，嚴(yán)重危害人類(lèi)健康；RA的治療有多種，包括外科手術(shù)、理療、替代療法等，但以藥物治療為主，使用的藥物包括免疫抑制劑、調(diào)節(jié)性抗類(lèi)風(fēng)濕藥、非甾體類(lèi)抗炎藥、腎上腺皮質(zhì)激素等；目前臨床上使用的各種抗風(fēng)濕藥物僅能減輕癥狀，不能根本阻止疾病的發(fā)展，并伴隨較強(qiáng)的毒副作用。因此，尋求研發(fā)高效低毒的抗RA新藥物、新技術(shù)是極為重要而緊迫的任務(wù)，而祖國(guó)傳統(tǒng)醫(yī)藥及少數(shù)民族醫(yī)藥，特別是廣西壯醫(yī)藥在防治RA上具有較大的潛力優(yōu)勢(shì)與鮮明特色。……